Department of Clinical Medicine

 Department of Clinical Medicine Research Publications

Publications

Search for Publications

List of Publications

Sort by: Date | Author | Title

Reimers, A., Helde, G., Becser Andersen, N., Aurlien, D., Surlien Navjord, E., Haggag, K., Christensen, J., Lillestølen, K. M., Nakken, K. O. & Brodtkorb, E. (2018). Zonisamide serum concentrations during pregnancy. Epilepsy Research, 144, 25-29. https://doi.org/10.1016/j.eplepsyres.2018.05.002
Stewart, L. (2002). Zoning in on music and the brain. Trends in Cognitive Sciences, 6(11), 451.
Sakthivel, S., Kjærgaard, K. D., Ivarsen, P., Langdahl, B. & Jørgensen, H. S. (2026). Zoledronic acid for chronic kidney disease–associated osteoporosis. Archives of Osteoporosis, 21(1), Article 45. https://doi.org/10.1007/s11657-026-01680-2
Granild-Jensen, J. B., Møller-Madsen, B., Rackauskaite, G., Farholt, S., Søndergaard, C., Sørensen, T. H., Vestergaard, E. T. & Langdahl, B. L. (2023). Zoledronate increases bone mineral density in non-ambulant children with cerebral palsy: A randomized, controlled trial. Developmental Medicine and Child Neurology, 65(S2), 67. https://doi.org/10.1111/dmcn.15595
Granild-Jensen, J. B. (2022). Zoledronate increases bone mineral density in non-ambulant children with cerebral palsy: A randomized, controlled trial. Abstract from DNPS Årsmøde 2022, Middelfart, Denmark.
Granild-Jensen, J. B., Møller-Madsen, B., Rackauskaite, G., Farholt, S., Søndergaard, C., Sørensen, T. H., Vestergaard, E. T. & Langdahl, B. L. (2023). Zoledronate increases bone mineral density in non-ambulant children with cerebral palsy: A randomized, controlled trial. The Journal of Clinical Endocrinology & Metabolism, 108(11), 2840-2851. https://doi.org/10.1210/clinem/dgad299
Granild-Jensen, J. B., Møller-Madsen, B., Rackauskaite, G., Farholt, S., Søndergaard, C., Vestergaard, E. T. & Langdahl, B. L. (2023). Zoledronate increases Bone Mineral Density in children with severe cerebral palsy: A randomized, controlled trial. 91.
Sørensen, J. S., Sani, F., Flemming, P., Ellermann, A., Kurt, K., Kjærsgård, P. & Birkebæk, N. (2009). ZnT8, GAD 65 and IA-2 autoantibodies in type 1 diabetes children at diagnosis and 3-5 years after the diagnosis, stratified for residual beta cell function. Hormone Research, (Suppl 3), 53.
Sørensen, J. S., Vaziri-Sani, F., Pociot, F., Kristensen, K., Brorsson, C., Lyngssø, L., Dolmer, B. & Birkebæk, N. (2010). ZnT8 autoantibody specificities at, and 3-5 years after clinical onset, associates with the age at diagnosis and the SLC30A8 gene polymorphism in Danish children. Pediatric Diabetes, 11(Suppl 14):24.
Smidt, K. & Rungby, J. (2012). ZnT3: a zinc transporter active in several organs. BioMetals, 25(1), 1-8. https://doi.org/10.1007/s10534-011-9490-x

Displaying results 31 to 40 out of 70980

Previous

1

2

3

4

5

6

7

8

9

10

Next

Revised 11.09.2025